The Emerging Evidence of the Parkinson Pandemic

E Ray Dorsey, Todd Sherer, Michael S Okun, Bastiaan R Bloem, E Ray Dorsey, Todd Sherer, Michael S Okun, Bastiaan R Bloem

Abstract

Neurological disorders are now the leading source of disability globally, and the fastest growing neurological disorder in the world is Parkinson disease. From 1990 to 2015, the number of people with Parkinson disease doubled to over 6 million. Driven principally by aging, this number is projected to double again to over 12 million by 2040. Additional factors, including increasing longevity, declining smoking rates, and increasing industrialization, could raise the burden to over 17 million. For most of human history, Parkinson has been a rare disorder. However, demography and the by-products of industrialization have now created a Parkinson pandemic that will require heightened activism, focused planning, and novel approaches.

Keywords: Parkinson disease; aging; demography; epidemiology; pesticides; smoking; solvents; survival.

Figures

Fig.1
Fig.1
World population 65 and older, 1990– 2040 [33, 34].
Fig.2
Fig.2
Projected global burden of Parkinson disease accounting for changes in aging, longevity, smoking rates, and industrialization, 1990– 2040.
Fig.3
Fig.3
Correlation between increasing gross domestic product (GDP) per capita and increasing Parkinson disease prevalence rate, 1990– 2016 [4, 35].

References

    1. Parkinson J (2002) An essay on the shaking palsy. J Neuropsychiatry Clin Neurosci 14, 223–236.
    1. Morris AD, Rose FC (1989) James Parkinson His Life and Times, Birkhauser, Boston, MA.
    1. (2018) Deaths associated with neurological conditions in England 2001 to 2014. Public Health England.
    1. GBD 2015 Neurological Disorders Collaborator Group (2017) Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol 16, 877–897.
    1. Savica R, Grossardt BR, Bower JH, Ahlskog J, Rocca WA (2016) Time trends in the incidence of parkinson disease. JAMA Neurol 73, 981–989.
    1. Darweesh SKL, Koudstaal PJ, Stricker BH, Hofman A, Ikram MA (2016) Trends in the Incidence of Parkinson Disease in the General Population: The Rotterdam Study. Am J Epidemiol 183, 1018–1026.
    1. Akushevich I, Kravchenko J, Ukraintseva S, Arbeev K, Yashin AI (2013) Time trends of incidence of age-associated diseases in the US elderly population: medicare-based analysis. Age Ageing 42, 494–500.
    1. Isotalo J, Vahlberg T, Kaasinen V (2017) Unchanged long-term rural-to-urban incidence ratio of Parkinson’s disease. Mov Disord 32, 474–475.
    1. GBD 2016 Parkinson’s Disease Collaborators (2018) Global, regional, and national burden of Parkinson’s disease in 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17, 939–953.
    1. Savica R, Grossardt BR, Bower JH, Ahlskog JE, Boeve BF, Graff-Radford J, Rocca WA, Mielke MM (2017) Survival and causes of death among people with clinically diagnosed synucleinopathies with parkinsonism: a population-based study. JAMA Neurol 74, 839–846.
    1. Rossi A, Berger K, Chen H, Leslie D, Mailman RB, Huang X (2018) Projection of the prevalence of Parkinson’s disease in the coming decades: Revisited. Mov Disord 33, 156–159.
    1. Darweesh SKL, Raphael KG, Brundin P, Matthews H, Wyse RK, Chen H, Bloem BR (2018) Parkinson matters. J Parkinsons Dis. doi:10.3233/JPD-181374.
    1. Morens DM, Folkers GK, Fauci AS (2009) What is a pandemic? J Infect Dis 200, 1018–1021.
    1. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM (2007) Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68, 384–386.
    1. Allen L (2017) Are we facing a noncommunicable disease pandemic? J Epidemiol Glob Health 7, 5–9.
    1. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM (2003) Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 157, 1015–1022.
    1. Dorsey E, Bloem BR (2018) The parkinson pandemic— a call to action. JAMA Neurol 75, 9–10.
    1. GBD 2013 DALYs and HALE Collaborators (2015) Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet 386, 2145–2191.
    1. Wanneveich M, Moisan F, Jacqmin-Gadda H, Elbaz A, Joly P (2018) Projections of prevalence, lifetime risk, and life expectancy of Parkinson’s disease (2010-2030) in France. Mov Disord. doi:10.1002/mds.27447.
    1. Scheperjans F, Pekkonen E, Kaakkola S, Auvinen P (2015) Linking smoking, coffee, urate, and Parkinson’s disease – a role for gut microbiota? J Parkinsons Dis 5, 255–262.
    1. Goldman SM (2014) Environmental toxins and Parkinson’s disease. Ann Rev Pharmacol Toxicol 54, 141–164.
    1. Roser M, Ritchie H, Fertilizer and pesticides.
    1. Mercola J (2017) Paraquat-banned in EU while US increasing use of this toxic killer. Take Control of Your Health, Mercola.
    1. Hakim D (2016) This pesticide is prohibited In Britain. Why is it still being exported? The New York Times, December 20, 2016.
    1. (2018) Fairchild Semiconductor Corp. (Mountain View Plant) Mountain View, CA Cleanup Activities US Environmental Protection Agency. .
    1. McCord CP (1932) Toxicity of trichloroethylene. J Am Med Assoc 99, 409–409.
    1. Strickland D, Bertoni JM (2003) Parkinson’s prevalence estimated by a state registry. Mov Disord 19, 318–323.
    1. Driver JA, Logroscino G, Gaziano JM, Kurth T (2009) Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72, 432–438.
    1. Schulz R, Beach SR (1999) Caregiving as a risk factor for mortality: The caregiver health effects study. JAMA 282, 2215–2219.
    1. Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A (2013) The current and projected economic burden of Parkinson’s disease in the United States. Mov Disord 28, 311–318.
    1. Dieleman JL, Baral R, Birger M, Bui AL, Bulchis A, Chapin A, Hamavid H, Horst C, Johnson EK, Joseph J, Lavado R, Lomsadze L, Reynolds A, Squires E, Campbell M, DeCenso B, Dicker D, Flaxman AD, Gabert R, Highfill T, Naghavi M, Nightingale N, Templin T, Tobias MI, Vos T, Murray CJ (2016) US spending on personal health care and public health, 1996-2013. JAMA 316, 2627–2646.
    1. Ypinga JHL, de Vries NM, Boonen LHHM, Koolman X, Munneke M, Zwinderman AH, Bloem BR (2018) Effectiveness and costs of specialised physiotherapy given via ParkinsonNet: a retrospective analysis of medical claims data. Lancet Neurol 17, 153–161.
    1. (2017) International Data Base. U.S. Census Bureau. Accessed September 2018.
    1. (2017) Population ages 65 and above, total. The World Bank, The World Bank. Accessed September 2018.
    1. GDP per capita. The World Bank, Accessed September 2018.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever